Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shan Peng

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Cell Reports|February 4, 2026
Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancerGuanghui Xu, Yuqin Li, Shan Peng, et al.
Optics Express|August 9, 2017
Picosecond mid-infrared optical parametric amplifier based on LiInSe<sub>2</sub> with tenability extending from 3.6 to 4.8 μmShi-Bo Dai, Ning Jia, Jia-Kang Chen, et al.
Medrxiv : the Preprint Server for Health Sciences|November 28, 2024
AI-Powered cellular morphometric biomarkers discovered in needle biopsy of prostatic cancer predict neoadjuvant androgen deprivation therapy response and prognosis: an international multicenter retrospective studyHong Yan, April W Mao, Dan Li, et al.
Eclinicalmedicine|June 8, 2026
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in ChinaChao Zhang, Ben-Yuan Jiang, Li-Xu Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth SuppressionChuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.
Molecular Cancer Therapeutics|June 23, 2021
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Shan Peng, Patrick G Pilié, et al.
Cancer Letters|March 26, 2026
AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumorsHong Yan, April W Mao, Dan Li, et al.
Nature Communications|February 6, 2026
Analysis of the transcriptomic and metabolomic landscape of prostate cancer with different anatomical origins using snFLARE-seq and mxFRIZNGRNDDongyin He, Haoran Hu, Kai Xiao, et al.
BMC Genomics|October 14, 2024
Microsatellite density landscapes illustrate short tandem repeats aggregation in the complete reference human genomeYun Xia, Douyue Li, Tingyi Chen, et al.
Cell Reports. Medicine|June 19, 2024
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)Chao Zhang, Yu-Xuan Sun, Ding-Cheng Yi, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Cell Reports|February 4, 2026
Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancerGuanghui Xu, Yuqin Li, Shan Peng, et al.
Optics Express|August 9, 2017
Picosecond mid-infrared optical parametric amplifier based on LiInSe<sub>2</sub> with tenability extending from 3.6 to 4.8 μmShi-Bo Dai, Ning Jia, Jia-Kang Chen, et al.
Medrxiv : the Preprint Server for Health Sciences|November 28, 2024
AI-Powered cellular morphometric biomarkers discovered in needle biopsy of prostatic cancer predict neoadjuvant androgen deprivation therapy response and prognosis: an international multicenter retrospective studyHong Yan, April W Mao, Dan Li, et al.
Eclinicalmedicine|June 8, 2026
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in ChinaChao Zhang, Ben-Yuan Jiang, Li-Xu Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth SuppressionChuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.
Molecular Cancer Therapeutics|June 23, 2021
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Shan Peng, Patrick G Pilié, et al.
Cancer Letters|March 26, 2026
AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumorsHong Yan, April W Mao, Dan Li, et al.
Nature Communications|February 6, 2026
Analysis of the transcriptomic and metabolomic landscape of prostate cancer with different anatomical origins using snFLARE-seq and mxFRIZNGRNDDongyin He, Haoran Hu, Kai Xiao, et al.
BMC Genomics|October 14, 2024
Microsatellite density landscapes illustrate short tandem repeats aggregation in the complete reference human genomeYun Xia, Douyue Li, Tingyi Chen, et al.
Cell Reports. Medicine|June 19, 2024
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)Chao Zhang, Yu-Xuan Sun, Ding-Cheng Yi, et al.
Pageof 18